N-hetero-ring-substituted amide derivative
AssigneeDaiichi Sankyo Company, Limited
InventorsShigeo Yamanoi, Madoka Hatta, Hidenori Namiki, Koji Matsumoto, Tomomi Yoshitomi
Life of this patent
Estimating the term…
Abstract
Compounds having an excellent hypoglycemic effect and β cell- or pancreas-preserving effects or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.
Claims14
A compound represented by general formula (I):
- wherein
- R1 represents
- * represents the point of attachment to the nitrogen atom, and
- R2 represents a methyl group or an ethyl group;
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of the following compounds:
- 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluoro -N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide;
- 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}1,2,4-oxadiazol-3-yl)-2-fluoro -N-[(3R,4S)-4-hydroxytetrahydrofuran-3-yl]benzamide;
- 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R,4S)-4-hydroxytetrahydrofuran-3-yl]benzamide;
- 4-(5-{(1R)-1-[4 -(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide;
- 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R)-2-oxotetrahydrofuran-3-yl]benzamide;
- 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-2-oxotetrahydrofuran-3-yl]benzamide;
- 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}- 1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-5-oxotetrahydrofuran-3-yl]benzamide;
- 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}- 1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R)-2-oxopyrrolidin-3-yl]benzamide;
- 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}- 1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]benzamide;
- 4-(5-{(1R)-1[4-(cyclopropylcarbonyl)phenoxy]propyl}--1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4S)-4-hydroxy-2-oxotetrahydrofuran-3-yl]benzamide;
- 4-(5-{(1R)-1[4-(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-[(3R)-2-oxopyrrolidin-3-yl]benzamide;
- 4-(5-{(1R)-1[4-(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]benzamide;
- 4-(5-{(1R)-1[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-hydroxy-2-oxotetrahydrofuran-3-yl]benzamide;
- 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide;
- and
- 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxyl]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4S)-4-hydroxytetrahydrofuran-3 -yl]benzamide;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.